Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation
Open Access
- 30 August 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 13 (9), 1236-1245
- https://doi.org/10.1002/lt.21124
Abstract
The recurrence of primary biliary cirrhosis (PBC) in the hepatic allograft may impact patient and graft survival with long-term follow-up. The efficacy of ursodeoxycholic acid (UDCA) for treatment of recurrent PBC after liver transplantation (LT) remains less well known. The aims of this study were as follows: 1) to determine the significance of recurrent PBC on overall survival among PBC patients who underwent LT, and 2) to determine the efficacy of UDCA treatment after LT in patients with recurrent PBC. A retrospective cohort study was conducted of 154 PBC patients who underwent LT with at least 1 yr of follow-up after transplantation from 1985 through 2005. A total of 52 patients with recurrent PBC were identified. After adjusting for age and gender, recurrent PBC was not associated with death or liver retransplantation (hazard ratio, 0.97, 95% confidence interval, 0.41–2.31; P = 0.9). A total of 38 patients with recurrent PBC received UDCA at an average dose of 12 mg/kg/day for a mean duration of 55 months. Over a 36-month period, an estimated 52% of UDCA-treated patients experienced normalization of serum alkaline phosphatase and alanine aminotransferase compared to 22% of untreated patients. There was no significant difference in the rate of histological progression between subgroups. UDCA did not influence patient and graft survival. In conclusion, the development of recurrent PBC has little impact on long-term survival or need for retransplantation. While UDCA therapy is associated with biochemical improvement, its role in delaying histologic progression remains unknown. In this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients. Liver Transpl 13:1236–1245, 2007. © 2007 AASLD.Keywords
This publication has 41 references indexed in Scilit:
- Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural historyLiver Transplantation, 2003
- Primary biliary cirrhosisThe Lancet, 2003
- Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up studyLiver Transplantation, 2001
- Replicative Senescence of Biliary Epithelial Cells Precedes Bile Duct Loss in Chronic Liver Allograft Rejection: Increased Expression of p21WAF1/Cip1 as a Disease Marker and the Influence of Immunosuppressive DrugsThe American Journal of Pathology, 2001
- Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single centerHepatology, 2001
- Management of primary biliary cirrhosisHepatology, 2000
- Transferrin receptor recycling in rat hepatocytes is regulated by protein phosphatase 2A, possibly through effects on microtubule-dependent transportHepatology, 1997
- Ursodeoxycholic acid in the treatment of primary biliary cirrhosisGastroenterology, 1994
- Primary biliary cirrhosis: Histological evidence of disease recurrence after liver transplantationJournal of Hepatology, 1993
- Evidence for disease recurrence after liver transplantation for primary biliary cirrhosisGastroenterology, 1989